ArticleOncotarget2020

Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism.

Abram Calderon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.